Skip to main content
SURAKSHA DIAGNOSTIC LIMITED logo

SURAKSHA DIAGNOSTIC LIMITED — Investor Relations & Filings

Ticker · SURAKSHA ISIN · INE877V01027 LEI · 335800SJSOH7ZQHTPO56 BSE.NS Human health and social work activities
Open in API
Filings indexed 144 across all filing types
Latest filing 2025-11-11 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS SURAKSHA

About SURAKSHA DIAGNOSTIC LIMITED

https://www.surakshanet.com

Suraksha Diagnostic Limited is a prominent diagnostic healthcare service provider primarily operating in Eastern India. The company offers a comprehensive range of pathology and radiology services, including clinical laboratory tests, molecular diagnostics, and advanced imaging such as MRI, CT scans, ultrasound, and X-rays. It operates a network of diagnostic centers and polyclinics, providing integrated healthcare solutions that encompass specialized consultations and preventive health check-ups. The organization is recognized for its commitment to quality, maintaining international standards through NABL and CAP accreditations. By leveraging advanced medical technology and a robust logistics framework for home collection, the company serves a diverse patient base, focusing on accurate clinical outcomes and accessible diagnostic care.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 80% confidence The document is a stock‐exchange filing under SEBI Regulation 47 enclosing scanned copies of the company’s unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2025 as published in newspapers. It contains the full interim financial data (even if in image form) rather than a brief notice or just an announcement. This matches the definition of an Interim/Quarterly Report, not merely an announcement of the report. H1 2025
2025-11-11 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated 10 November 2025 announcing the unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2025. It includes detailed financial performance data such as total income, EBITDA, profit after tax, EPS, and operational highlights. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of financial results. The content is typical of an Earnings Release, providing key financial highlights and management commentary on quarterly and half-year results. The document length (7328 characters) and detailed financial data confirm it is not merely an announcement or certification but a substantive financial report for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2026
2025-11-10 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is dated 10 November 2025 and is addressed to stock exchanges referencing Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It mentions an upcoming Earnings Call scheduled for 11 November 2025 and encloses an Investor Presentation on unaudited financial results for the quarter and six months ended 30 September 2025. The document includes detailed financial data such as Profit & Loss, Balance Sheet, Cash Flows, and key operating metrics for Q2 and H1 FY26. The content is a detailed presentation intended for investors, focusing on financial performance, business highlights, and management commentary. It is not a transcript of the call, nor a brief earnings release, but a comprehensive presentation. Therefore, the document fits the category of Investor Presentation (IP).
2025-11-10 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI LODR detailing the outcome of the Board meeting held on November 10, 2025, where the Board approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. It includes the Independent Auditor’s Review Report (limited review) and a full Statement of Unaudited Standalone Financial Results with detailed financial tables prepared under Ind AS 34. This constitutes a comprehensive interim/quarterly report rather than merely an earnings highlight or a short announcement, so it should be classified as an Interim / Quarterly Report (IR). H1 2026
2025-11-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification to stock exchanges about an upcoming earnings call scheduled for November 11, 2025, to discuss the Q2 and H1 FY 2025-26 financial results. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The document includes details about the event, participants, dial-in numbers, and instructions for pre-registration. It explicitly states that the earnings call will discuss publicly available financial information and that an investor presentation will be made available on the company's website. The document does not contain actual financial statements or detailed financial analysis but serves as an announcement of the earnings call event. According to the classification rules, such a document announcing an earnings call is best classified as a Call Transcript (CT) category, as it relates to the full text transcript or announcement of a conference call event. However, since this document is only the intimation or schedule of the earnings call and not the transcript itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory disclosure about the event rather than the transcript or the earnings release itself. The document length is about 5221 characters, which is not extremely short, but the content is clearly an announcement of the earnings call schedule, not the earnings release or transcript. Therefore, the best fit is Regulatory Filings (RNS).
2025-11-05 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-11-03 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.